BioSpace News Archive

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that Dr. Hua Jiang (“Dr. Jiang”) has been appointed as Executive Director of the Company.

Harmonic Bionics, the robotics company for augmenting human movement, announced today that Healthlink Holdings Ltd. will be the exclusive distributor of Harmony SHR™ in the Hong Kong and Macau territories.

Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today announced the appointment of Niall Condon as president of its Manufacturing Division, with immediate effect.

Orca Bio today announced Precision-T, its pivotal Phase 3 study, is open.

NervGen Pharma Corp., (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, will present the study design for its upcoming Phase 1b/2a Alzheimer’s disease clinical trial at the 2022 Alzheimer’s Association International Conference (AAIC) on August 3, 2022.

Britannia Life Sciences Inc. (CSE: BLAB) (“Britannia” or the “Company”) is pleased to provide its financial results for the three- and twelve-month periods ended March 31, 2022.

Twist Bioscience and Biotia Receive Expanded Emergency Use Authorization to Report Genetic Variants of SARS-CoV-2.

ŌNŌCOR LLC is excited to announce the first-in-human use of the ŌNŌ endovascular retrieval system for removal of an intracardiac tumor. Intracardiac tumors affect thousands of patients around the world annually, but prior to ŌNŌ, open-heart surgery was required for removal.

Amgen (NASDAQ: AMGN) will host a webcast call for the investment community in conjunction with the International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung Cancer (WCLC) at 12:00 p.m. ET on Monday, Aug. 8, 2022.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter 2022.